EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis

Rosaria Benedetti, Ugo Chianese iD, Chiara Papulino, Lucia Scisciola, Mirko Cortese, Pietro Formisano, Nunzio Del Gaudio, Serena Cabaro, Vittoria D'Esposito, Ada Pesapane, Mariarosaria Conte, Giuseppe Signoriello und 3 weitere

European Journal of Heart Failure · 01.05.2025 · 27 (5) · 844-856

DOI: 10.1002/ejhf.3566 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Heart Failure, online erschienen am 14.01.2025. Verfasst von Rosaria Benedetti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Myocytes, Cardiac, Hyperglycemia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Plan for PNRR Complementary Investments, Ministero dell'Università e della Ricerca (MUR) e dal Ministero della Salute (Italian Government), Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Hyperglycaemic conditions increase cardiac stress, a common phenomenon associated with inflammation, aging, and metabolic imbalance. Sodium–glucose cotransporter 2 inhibitors, a class of anti-diabetic drugs, showed to improve cardiovascular functions although their mechanism of action has not yet been fully established. This study investigated the effects of empagliflozin on cardiomyocytes following high glucose exposure, specifically focusing on inflammatory and metabolic responses. Methods and results A three-part strategy was formulated: (i) a meta-analysis of selected randomized clinical trials was carried out to assess the anti-inflammatory effects of empagliflozin in diabetic patients; (ii) the impact of empagliflozin on human cardiomyocyte AC16 cells exposed to normal (5 mM) and high (33 mM) glucose concentrations for 2 and 7 days was explored by evaluating gene expression and protein levels of pivotal markers associated with cardiac inflammation, stress, endoplasmic reticulum damage, and calcium modulation; (iii) in silico data from bioinformatic analyses were exploited to construct an interaction map delineating the potential mechanism of action of empagliflozin on cardiac tissue. Empagliflozin reversed high-glucose mediated alterations at the transcriptional level, decreasing inflammatory, metabolic, and aging signatures. Specifically, in vitro experiments on human cardiomyocytes, meta-analyses of clinical data on inflammatory biomarkers from diabetic peripheral blood samples, and sequencing of pathological human heart tissues, all support that empagliflozin exerts anti-inflammatory effects both systemically and directly in cardiac tissue, on cardiomyocytes.

Conclusion

Our study provides insights based on robust mechanistic data for optimizing heart failure management and highlights the intricate interplay between diabetes, inflammation, aging, and cardiovascular health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesMyocytes, CardiacHyperglycemiaSodium-Glucose Transporter 2 InhibitorsInflammationHumans

Stichwörter der Autor:innen

EmpagliflozinGlucoseHuman cardiomyocytesInflammaging

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Program of Medical Epigenetics, Vanvitelli Hospital, Naples, Italy.
  • Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
  • University of Campania Luigi Vanvitelli, Caserta, Italy.
  • Department of Translational Medicine, University of Naples "Federico II", Naples, Italy.

ORCID-Profile: Ugo Chianese

Förderung

  • National Plan for PNRR Complementary Investments
  • Ministero dell'Università e della Ricerca (MUR) e dal Ministero della Salute (Italian Government)
  • Ministero dell'Università e della Ricerca

Zitieren

APA

Benedetti, R., Chianese, U., Papulino, C., Scisciola, L., Cortese, M., Formisano, P., Del Gaudio, N., Cabaro, S., D'Esposito, V., Pesapane, A., Conte, M., Signoriello, G., Barbieri, M., Altucci, L., & Paolisso, G. (2025). Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis. European Journal of Heart Failure, 27(5), 844-856. https://doi.org/10.1002/ejhf.3566

Vancouver

Benedetti R, Chianese U, Papulino C, Scisciola L, Cortese M, Formisano P, et al. Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis. European Journal of Heart Failure. 2025;27(5):844-856. doi:10.1002/ejhf.3566

BibTeX
@article{Benedetti2025,
  author = {Benedetti, Rosaria and Chianese, Ugo and Papulino, Chiara and Scisciola, Lucia and Cortese, Mirko and Formisano, Pietro and Del Gaudio, Nunzio and Cabaro, Serena and D'Esposito, Vittoria and Pesapane, Ada and Conte, Mariarosaria and Signoriello, Giuseppe and Barbieri, Michelangela and Altucci, Lucia and Paolisso, Giuseppe},
  title = {Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis},
  journal = {European Journal of Heart Failure},
  year = {2025},
  volume = {27},
  number = {5},
  pages = {844--856},
  doi = {10.1002/ejhf.3566}
}
Kostenlos starten →